Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

Saunders FJ . Some aspects of relation of structure of steroids to their prostate stimulating effects In: Vollmer ED, (eds). Prostate and related tissues Washington, DC: US Governing Printing Office 1963 139–159

Rosenberg AG, von Eschenbach AC . Hormonal therapy for prostate cancer Semin Surg Oncol 1990 6: 71–76

Kyprianou N, English HF, Isaacs JT . Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation Cancer Res 1990 50: 3748–3753

Stein CA, Narayanan R . Antisense oligodeoxynucleotides Curr Opin Oncol 1994 6: 587–594

Wagner R . Gene inhibition using antisense oligodeoxynucleotides Nature 1994 372: 333–335

Cucco C, Calabretta B . In vitro and in vivo reversal of multidrug resistance in a human leukemia–resistant cell line by mdr1 antisense oligodeoxynucleotides Cancer Res 1996 56: 4332–4337

Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D . Antitumor activity of a phoshorothioate antisense oligodeoxynucleotide targeted against C-raf kinase Nat Med 1996 2: 668–675

Ziegler A, Luedke GH, Fabbro D, Altman KH, Stahel RA, Zangemeister-Wittke U . Induction of apoptosis in small cell lung cancer cells by antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence J Natl Cancer Inst 1997 89: 1027–1036

Jansen B, Schlagbauer-Wadl H, Brown BD et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice Nat Med 1998 4:

Khuri FR, Kurie JM . Antisense approaches enter the clinic Clin Cancer Res 2000 6: 1607–1610

Eder IE, Culig Z, Ramoner R et al. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides Cancer Gene Ther 2000 7: 997–1007

Gottlieb B, Beitel LK, Lumbroso R, Pinsky L, Triforo M . Update of the androgen receptor gene mutations database Hum Mutat 1999 14: 103–114

Culig Z, Hobisch A, Cronauer MV et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor Cancer Res 1994 54: 5474–5478

Nazareth LV, Weigel NL . Activation of the human androgen receptor through a protein kinase A signaling pathway J Biol Chem 1996 271: 19900–19907

Culig Z, Hobisch A, Hittmair A et al. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts? Histol Histopathol 1997 12: 781–786

Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 1995 9: 401–406

Hobisch A, Culig A, Radmayr C, Bartsch G, Klocker H, Hittmair A . Distant metastases from prostatic carcinoma express androgen receptor protein Cancer Res 1995 55: 3068–3072

Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding Anal Biochem 1976 72: 248–254

Geiger T, Muller M, Monia BP, Fabbro D . Antitumor activity of a c-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice Clin Cancer Res 1997 3: 1179–1185

Stevenson JP, Yao KS, Gallagher M et al. Phase I clinical/pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A) J Clin Oncol 1999 17: 2227–2236

Cunningham CC, Holmlund JT, Schiller JH et al. A phase I trial of C-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer Clin Cancer Res 2000 6: 1626–1631

Tortora G, Bianco R, Damiano V et al. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production Clin Cancer Res 2000 6: 2506–2512

Nemunaitis J, Holmlund JT, Kraynak M et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-a, in patients with advanced cancer J Clin Oncol 1999 17: 3586–3595

Yuen AR, Halsey J, Fisher GA et al. Phase I study of an antisense oligonucleotide to protein kinase C-a (ISIS 3521/CGP 64128A) in patients with cancer Clin Cancer Res 1999 5: 3357–3363

Costa-Pereira AP, McKenna SL, Cotter TG . Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis Br J Cancer 2000 82: 1827–1834

Miyake H, Tolcher A, Gleave ME . Antisense bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model Cancer Res 1999 59: 4030–4034

Miyake H, Monia BP, Gleave ME . Inhibition of progression to androgen-indepence by combined adjuvant treatment with antisense BCL-X and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model Int J Cancer 2000 86: 855–862

Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM . Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells Proc Natl Acad Sci USA 2000 97: 9042–9046

Nguyen JT . Vascular endothelial growth factor as a target for cancer gene therapy Adv Exp Med Biol 2000 465: 447–456

Wang H, Liu Y, Wei L, Guo Y . Antisense IGF and antisense IGF-IR therapy of malignancy Adv Exp Med Biol 2000 465: 265–272

Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 1989 321: 419–424

Labrie F, Belanger A, Simard J, Labrie C, Dupont A . Combination therapy for prostate cancer — endocrine and biologic basis of its choice as new standard first-line therapy Cancer 1993 71: 1059–1067

Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A . Androgen receptor status of lymph node metastases from prostate cancer Prostate 1996 28: 129–135

Veldscholte J, Ris-Stalpers C, Kuiper GGJM et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem Biophys Res Commun 1990 17: 534–540

Culig Z, Hobisch A, Cronauer MV et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone Mol Endocrinol 1993 7: 1541–1550

Zhao X-Y, Malloy PJ, Krishnan AV et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 2000 6: 703–706

Sadar MD . Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways J Biol Chem 1999 274: 7777–7783

Whitfield GK, Jurutka PW, Haussler CA, Haussler MR . Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function J Cell Biochem 1999 Suppl 32–33 110–122

Kandimalla ER, Yu D, Zhao Q, Agrawal S . Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure–immunostimulatory activity relationships Bioorg Med Chem 2001 9: 807–813

Stein CA, Cheng Y-C . Antisense oligonucleotides as therapeutic agents — is the bullet really magical? Science 1993 261: 1004–1012

Stein CA . Does antisense exist? Nat Med 1995 1: 1119–1121

Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ . Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal therapy of lymphoma Blood 1997 89: 2994–2998

Rubenstein M, Mirochnik Y, Chou P, Guinan P . Antisense oligonucleotides intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice J Surg Oncol 1996 62: 194–200

Rubenstein M, Mirochnik Y, Ray V, Guinan P . Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors Med Oncol 1997 14: 131–136

Bost F, McKay R, Dean NM, Potapova O, Mercola D . Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family Methods Enzymol 1999 314: 342–362

Bost F, Potapova O, Liu C et al. High frequency regression of established human prostate carcinoma PC3 xenografts by systemic treatment with antisense JUN kinase Prostate 1999 38: 320

Gregory CW, Hamil KG, Kim D et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes Cancer Res 1998 58: 5718–5724

Agus DB, Scher HI, Higgins B et al. Response of prostate cancer to anti–Her-2/neu antibody in androgen-dependent and -independent human xenograft models Cancer Res 1999 59: 4761–4764

Agus DB, Cordon-Cardo C, Fox W et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence J Natl Cancer Inst 1999 91: 1869–1876